| Stewart M Kerr, MD | |
|
1919 Lathrop St, Fairbanks, AK 99701-5937 | |
| (907) 459-3500 | |
| Not Available |
| Full Name | Stewart M Kerr |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 26 Years |
| Location | 1919 Lathrop St, Fairbanks, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932157732 | NPI | - | NPPES |
| 2014621 | Medicaid | WA | |
| 1679991 | Medicaid | AK |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairbanks Memorial Hospital | Fairbanks, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tanana Valley Clinic Llc | 5698056901 | 105 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
A new study in the journal Family Process shows that infants appear to be active participants in complex interactional sequences with their parents far earlier than previously thought.
Rice University biomedical engineers have developed a new technique for growing cartilage from human embryonic stem cells, a method that could be used to grow replacement cartilage for the surgical repair of knee, jaw, hip, and other joints.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago
| Entity Name | Anchorage Fracture And Orthopaedic Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285677054 PECOS PAC ID: 7517914187 Enrollment ID: O20050405001438 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
A new study in the journal Family Process shows that infants appear to be active participants in complex interactional sequences with their parents far earlier than previously thought.
Rice University biomedical engineers have developed a new technique for growing cartilage from human embryonic stem cells, a method that could be used to grow replacement cartilage for the surgical repair of knee, jaw, hip, and other joints.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago
| Entity Name | Medical Network Of Alaska Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538414834 PECOS PAC ID: 3072618859 Enrollment ID: O20070424000329 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
A new study in the journal Family Process shows that infants appear to be active participants in complex interactional sequences with their parents far earlier than previously thought.
Rice University biomedical engineers have developed a new technique for growing cartilage from human embryonic stem cells, a method that could be used to grow replacement cartilage for the surgical repair of knee, jaw, hip, and other joints.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago
| Entity Name | Orthopaedic Research Clinic Of Alaska Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760691612 PECOS PAC ID: 7810097946 Enrollment ID: O20070703000059 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
A new study in the journal Family Process shows that infants appear to be active participants in complex interactional sequences with their parents far earlier than previously thought.
Rice University biomedical engineers have developed a new technique for growing cartilage from human embryonic stem cells, a method that could be used to grow replacement cartilage for the surgical repair of knee, jaw, hip, and other joints.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago
| Entity Name | Kenai Spine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497002968 PECOS PAC ID: 2567617707 Enrollment ID: O20130219000472 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
A new study in the journal Family Process shows that infants appear to be active participants in complex interactional sequences with their parents far earlier than previously thought.
Rice University biomedical engineers have developed a new technique for growing cartilage from human embryonic stem cells, a method that could be used to grow replacement cartilage for the surgical repair of knee, jaw, hip, and other joints.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago
| Entity Name | Tanana Valley Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922559558 PECOS PAC ID: 5698056901 Enrollment ID: O20161228001991 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
A new study in the journal Family Process shows that infants appear to be active participants in complex interactional sequences with their parents far earlier than previously thought.
Rice University biomedical engineers have developed a new technique for growing cartilage from human embryonic stem cells, a method that could be used to grow replacement cartilage for the surgical repair of knee, jaw, hip, and other joints.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stewart M Kerr, MD Po Box 73720, Fairbanks, AK 99707-3720 Ph: (907) 459-3500 | Stewart M Kerr, MD 1919 Lathrop St, Fairbanks, AK 99701-5937 Ph: (907) 459-3500 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
A new study in the journal Family Process shows that infants appear to be active participants in complex interactional sequences with their parents far earlier than previously thought.
Rice University biomedical engineers have developed a new technique for growing cartilage from human embryonic stem cells, a method that could be used to grow replacement cartilage for the surgical repair of knee, jaw, hip, and other joints.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago
Jimmy M. Tamai, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1275 Sadler Way, Ste 101, Fairbanks, AK 99701 Phone: 907-374-4463 Fax: 907-374-7072 | |
Daniel R Johnson, D.O. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 3745 Geist Road, Fairbanks, AK 99709 Phone: 907-456-3338 | |
Dr. Robert Denison Dingeman, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 751 Old Richardson Hwy, Suite 101, Fairbanks, AK 99701 Phone: 907-452-2663 Fax: 907-456-3033 | |
Neal Everson, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2310 Peger Rd Ste 105, Fairbanks, AK 99709 Phone: 907-479-2663 Fax: 907-479-2691 | |
Dr. Mark Alan Wade, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2310 Peger Rd, Ste 105, Fairbanks, AK 99709 Phone: 907-479-2663 Fax: 907-479-2691 | |
Dr. David Witham, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1001 Noble St, Fairbanks, AK 99701 Phone: 907-459-3500 Fax: 907-459-3532 | |
Dr. Gary Ian Molk, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1919 Lathrop St Ste 105, Fairbanks, AK 99701 Phone: 907-459-3545 Fax: 907-328-0474 |